Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Single Arm Clinical Trial to Evaluate the Tolerability, Safety and Efficacy of RJMty19 in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

NCT06314828 is registered in ClinicalTrials.gov with Guangdong Ruishun Biotech Co., Ltd as lead sponsor.

NCT NCT06314828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06314828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Single Arm Clinical Trial to Evaluate the Tolerability, Safety and Efficacy of RJMty19 in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Lead sponsor
Guangdong Ruishun Biotech Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 20, 2024
Completion date
May 20, 2027
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin's lymphoma